Press Releases

Osmotica Pharmaceuticals Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals

(PRESS RELEASE) BRIDGEWATER, N.J. — Osmotica Pharmaceuticals, plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC (“Alora”) pursuant to which Alora will acquire Osmotica’s portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 million.

“Today’s announcement is a meaningful step in the transformation of our business and aligns with our strategy of building a portfolio of growth assets in ocular aesthetics,” said Brian Markison, CEO of Osmotica Pharmaceuticals. “The legacy business has been an important part of our evolution, and we would like to recognize the excellent performance of our employees as they have remained focused throughout this process. The proceeds generated by the sale will be used to retire a substantial portion of our outstanding indebtedness and position us to accelerate the commercialization efforts of our flagship product, UPNEEQ. Since the introduction of UPNEEQ, our confidence in the brand has continued to grow, and we believe that this is the right time to further focus on this tremendous asset.

Photo Gallery

INVISION Races to Miami with Ferrari and Ray-Ban

Photo Gallery

11 Images That Show Why The Novel Eye in North Kingstown Was Named One of America’s Finest Optical Retailers for 2023-24

Photo Gallery

11 Images That Show Why Respect Eyecare in Calgary Was Named One of (North) America’s Finest Optical Retailers

“Alora Pharmaceuticals is an excellent home for our legacy business given its diverse portfolio and dedication to high-quality branded and generic products,” added Markison.

“Alora Pharmaceuticals is excited to welcome the Osmotica team to our growing company. This acquisition will immediately bolster our platform of generic and branded product lines and will contribute to the long-term growth of our contract research and development and manufacturing capabilities,” said Art Deas, CEO of Alora.

The Boards of Directors of both Osmotica and Alora have approved the transaction, which is expected to close in the third quarter of 2021.

Barclays Bank PLC and Jefferies LLC are acting as financial advisors, and Ropes & Gray LLP is acting as legal advisor to Osmotica. TAP Advisors is acting as exclusive financial advisor, and Nelson Mullins Riley & Scarborough LLP is acting as legal advisor to Alora on the transaction.

Press Releases

Recent Posts

Here’s How Independent Eyecare Can Win the OD Recruitment Game

INVISION’s strategies for standing out in a crowded market and attracting optometric talent.

12 hours ago

How Small Eyecare Businesses Can Afford Medical Benefits for Employees

It's about finding the right fit between valuable employee benefits and what's financially feasible for…

12 hours ago

How My Degree Helped Me Make a Difference in My Community

I am deeply grateful for the early wisdom my parents instilled in me from a…

12 hours ago

Safilo Signs a Perpetual License Agreement For David Beckham Eyewear

Discover Safilo Group's perpetual license agreement for David Beckham Eyewear, showcasing timeless British sophistication and…

12 hours ago

ZEISS Sponsors French Skipper Thimoté Polet for the Transat CIC Race Stopping in New York City

Polet will compete in the Class40 category, and his boat will bear the name and…

13 hours ago

Marcolin, Exclusive Licensing Agreement Signed with K-Way

Marcolin and K-Way forge exclusive eyewear partnership: sporty fashion meets innovation.

13 hours ago

This website uses cookies.